1 / 13 Next Page
Information
Show Menu
1 / 13 Next Page
Page Background

Page 25

Regenerative & Precision Medicine 2016

December 1-2, 2016

Volume 7, Issue 3(Suppl)

J Tissue Sci Eng

ISSN: 2157-7552 JTSE, an open access journal

conferenceseries

.com

December 1-2, 2016 | San Antonio, USA

Global Congress on

Tissue Engineering, Regenerative &

Precision Medicine

Brian M Mehling et al., J Tissue Sci Eng 2016, 7:3(Suppl)

http://dx.doi.org/10.4172/2157-7552.C1.030

Analysis of outcomes following mesenchymal stem cell therapy in subjects with musculoskeletal

conditions

Brian M Mehling, Marine Manvelyan and Dong-Cheng Wu

Blue Horizon International LLC, USA

Wuhan University, China

Wuhan Hongqiao Brain Hospital, China

M

usculoskeletal conditions are major public health problems and often associated with reduced function and pain.

Musculoskeletal-related pain is affecting more than one third of the adult population worldwide. Pain reduction is one

of the main outcomes to determine the success of therapy of subjects with most common orthopedic conditions. Inflammation

plays an important role in the occurrence of acute and chronic musculoskeletal-related pain. Numerous investigations suggest

that Mesenchymal Stem Cells (MSCs) represent a valuable tool for therapy of inflammation and regeneration of tissue damage.

BHI Therapeutic Sciences offers a novel method of arthritis therapy using a patient’s own stromal vascular fraction (SVF) cells

including MSCs. The therapy is available at Malacky Hospital in Slovakia. Blue Horizon International Slovakia is licensed by

the Ministry of Health of Slovak Republic to provide adipose stem cell therapies for orthopedic joint applications: Knees, hips,

shoulders and ankles. Procedures utilize cutting-edge technology and adult stem cells only. Results from patients’ follow-up

examinations and MRI scans showed that stem cell therapy was safe for the patients. Follow-up examination results conducted

10 days, 3 and 6 months after therapy have shown significant improvement of clinical condition relating to pain relief, improved

mobility, which was shown also on the follow-up MRI scans of the affected joints.

Biography

Brian M Mehling is a practicing American Orthopedic Trauma Surgeon, Researcher and Philanthropist. He started his path in medicine through undergraduate study

at Harvard University, obtaining Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University. Completing his degree of Medicine at

Wright State University School of Medicine, he has received Post graduate education through Residencies and Fellowships at St. Joseph’s Hospital in Paterson,

NJ and the Graduate Hospital in Philadelphia, PA, while pursuing PhD in Chemistry. He operates his own practice, Mehling Orthopedics, in both West Islip, NY

and Hackensack, NJ.

mmanvelyan@bluehorizonhospital.com